{"name":"CytoDyn, Inc.","slug":"cytodyn-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Optimized Background Regimen","genericName":"Optimized Background Regimen","slug":"optimized-background-regimen","indication":"HIV-1 infection (as background regimen component in clinical trials)","status":"phase_3"}]}],"pipeline":[{"name":"Optimized Background Regimen","genericName":"Optimized Background Regimen","slug":"optimized-background-regimen","phase":"phase_3","mechanism":"An optimized antiretroviral background regimen designed to enhance the efficacy of leronlimab (a CCR5 antagonist) in HIV treatment.","indications":["HIV-1 infection (as background regimen component in clinical trials)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiugJBVV95cUxPYVk3VXdaWnRuNDhFRjQ5ZlZXeFU5R1JmNDVEQjZxZU1ZejJNODRnNzJSN00zaG53aEJlelFsVUtyRFVKMC1YSnQ5cHctZjBoNnNIcWlwZ2toUEhBLW9xOHpjb084RVNpUHJuNF9HX19YUUxpLWljbmJPMjVGOWx5T1V6eVBURVBDbGZCX1lzd2NKdFRuQ1NlYm1Ra2o0Z01SRkI0bEE5eXlVS292bEdTVUJmZDNSVlJwYU5wdGRhOHNuaFIxTzBaT2I5YlVqbVpWU3Z0LTgyWVR4NzZPYWN6ODJ5cnBZYzBTYkdSRXA3LTZRWlFybzk5dG4ycmNXVk5ZVzBuQ1dWamhCa01veThhcU9pR0Rla3c1V3lWcVppeXJFZ0hsenNPcUJBdEFaWVVQNEJBT1pHS3k4dw?oc=5","date":"2026-03-03","type":"trial","source":"PR Newswire","summary":"Creatv Bio's LifeTracDx® Blood Test Utilized as Exploratory Biomarker in CytoDyn's Phase 2 Study in Patients with Relapsed/Refractory Metastatic Colorectal Cancer - PR Newswire","headline":"Creatv Bio's LifeTracDx® Blood Test Utilized as Exploratory Biomarker in CytoDyn's Phase 2 Study in Patients with Relaps","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE0tdmFscEtJbmtkNFF3azg4dHh6YUMwZ1FBZDJxR0ZYUkJvRmR3bUVEUFhxQUxaNk5YV0RieEI1RmhTUXd2Rm9TZlFHUDBZaVpFR3dTWlhB?oc=5","date":"2026-02-14","type":"pipeline","source":"Stock Titan","summary":"CYDY Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan","headline":"CYDY Financials: Income Statement, Balance Sheet & Cash Flow","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxNNnhnZ0x3VkpDMGtPTDZQQVVxZVVwbHpzSS1OdlRNc2QtVk1TTFdzNW8wYWJvbkw4anBUQUhHR1QwcElPTVhYM3d6UEhoVDI1amJDZWczU013dkp5TDhqVlF5b2JzUkRjaGNUREozNHBPZHdlN3NMeDJCS1hEU0hoR0pjX2V3Z3RaNlZXR1k2Qkg?oc=5","date":"2026-01-26","type":"pipeline","source":"Investment Executive","summary":"Biotech exec gets prison for securities fraud - Investment Executive","headline":"Biotech exec gets prison for securities fraud","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxPRzJTWnp0Z1F5dEtTNFpRUUFmNzNUY3p2N0djLVhGUUR2WEZmTlFiLW1jc3VvTlIxY1ZRVTZfVGNqSDdpNDFJX1VoNkhlNHRXNHlSMjZNQWZHMU8ySW5BUlp1dzR0Q1IwbFAzcmd2a1RnZ3pzWG5WdzZ6REV0cV9jTGhrNWdLTTU4OEplMFpGbnlUWU9MdkNhb1lPNWxNQ3RYQW9HTkdQVXhjTERraTNiTVBncTYzdzZSRVljWkVpWDJmMUVKN19V?oc=5","date":"2025-06-27","type":"pipeline","source":"Fierce Biotech","summary":"CytoDyn must face investor lawsuit alleging misleading claims in COVID, HIV drug debacle - Fierce Biotech","headline":"CytoDyn must face investor lawsuit alleging misleading claims in COVID, HIV drug debacle","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwJBVV95cUxNN0EyTXotWmZqbVcyOFlWSXR1ZlltMk1FamNoMVZsYWFwSHB0bWZ4bGl3bzFCSm01R09zZGZTZ0tRaUdlSnpWQXRDWXFkR0hoS0tpZFBwMUdDVm1ZMV84RndkSGFxbVdrWDhUTzkzLW1jZ3hTeTlZcWhTVXFoMC1RUUVLdklmdkhEWm5Ddm1BY0pOMFc5NkMxYXAzN0xaekQwV0FSb1lZaVliTzF6RmN1Z2RzQjFEVk9iaDFBZHFTT3k5RVNMakJYbUZUNWRPSGxjUXA4Y0pPbG42UTRqb1pCc0pXQ0JqX1hXYW1HZUhoaFRvZkVlbTNVY3Z0LVR1amJiNzdSRVk4aGZPSjdrRWw5NjRLamVQZzhjeXF2dGlTemFDU1NmSjA2Z0JGNA?oc=5","date":"2025-05-30","type":"trial","source":"BioSpace","summary":"Clinical Trials Demonstrate Monitoring PD-L1 Upregulation Using LifeTracDx Blood Test Could Support New Treatment Path for Metastatic Triple Negative Breast Cancer - BioSpace","headline":"Clinical Trials Demonstrate Monitoring PD-L1 Upregulation Using LifeTracDx Blood Test Could Support New Treatment Path f","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOSWFlNkJUYVhrTU43MEh4Qm9VeFlsQWxFOEt2YTlIXzNNMnRyM1Ria3BlVTlvQjk1cElfczFxSkR4cWNlWFI2NkcxSDB4d3lCZVdPcVQzbnhheW1LTUhPOHRPeUdsQlI3c3Nra1cySGRnUzlhTDBWeUdmMEp1U3JFNFo0R195Y2JvekYyVVpTbE9VVGlpWi1KQ05VeURwV09PRXRtNkk4U0w2amVFd0hXVklpeXNmTE1k?oc=5","date":"2025-05-06","type":"pipeline","source":"CytoDyn Inc.","summary":"CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer - CytoDyn Inc.","headline":"CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPSWh0LVRTMFU3dHBKNzBHU2Fkc1BGY21LNVJKRk1BeEFGM2JGaTI0aUVWUXFWeXNyaFo2dGtVZmNMTGh2Z1FRSFg1Q1VFQ3RBbGJqdVlsQVVYaUZBMHI1bllqSE1Vemd6RkNHVW8wZTdzeFVJaTFZajgteDVPdlB4SlhKLVowYmpDWkxBQzdFVGhhaWpK?oc=5","date":"2024-10-30","type":"pipeline","source":"CytoDyn Inc.","summary":"CytoDyn Appoints Dr. Melissa Palmer, M.D., as Lead Consultant in Hepatology; Announces Follow-Up Inflammation Studies with SMC Laboratories - CytoDyn Inc.","headline":"CytoDyn Appoints Dr. Melissa Palmer, M.D., as Lead Consultant in Hepatology; Announces Follow-Up Inflammation Studies wi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiTEFVX3lxTFBCZkVFT3R3WW85WXFFSHRUcHhLRmV3YkxrazZ3UXZYZDJCNGVCSVoyc2s3ZWZlUDU4UmdNbG5GV28xSEU2U1E4ZmtXQ1Y?oc=5","date":"2023-11-15","type":"regulatory","source":"Manila Standard","summary":"Chiral Pharma, Cytodyn Inc. to secure FDA approval for possible COVID-19 drug - Manila Standard","headline":"Chiral Pharma, Cytodyn Inc. to secure FDA approval for possible COVID-19 drug","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNUExrTWQwdjI5eHdOWlFJLXZmQmdwTnd1OS1lcERLbTJ3RkU2Q01tV21MaTZtbEdhWm9fZER6ZWpvSm41ODNOSjVEWUZ2cXUteENJbWkyNkI1dGFJaUhvSUpoc1pBTWlHX0dkZUswbE5GN2l5RDNoX2dRRXBId2Z3Wmg5amI4bHdQdTVQeVBFX01aVU5PeHRka1U2ZFRvaG9ad1V3enBYelUyOTV6?oc=5","date":"2023-03-28","type":"pipeline","source":"seekingalpha.com","summary":"CytoDyn: On The Cusp Of A New Beginning, Existing Shareholders Beware (OTCMKTS:CYDY) - seekingalpha.com","headline":"CytoDyn: On The Cusp Of A New Beginning, Existing Shareholders Beware (OTCMKTS:CYDY)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxONWRWVWxZODJtUmNVVXFzWXpPVFJwM0Z2Vnc2WUptZ2RwckVldnBpd0I1VEkwU2V6U1Rma3FQSnF0aGJFZVZ6QlpmdFpCcXlGTWNLLTdieDU4SHROMWJ4empEZXZHVEJpTVlzcHpCQ3Y0VnVkRVg0Z2daYlZCbDFCaE0yeWllQ0wtMWc?oc=5","date":"2022-01-25","type":"pipeline","source":"The Business Journals","summary":"Embattled CytoDyn CEO Pourhassan is booted by the board - The Business Journals","headline":"Embattled CytoDyn CEO Pourhassan is booted by the board","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2021-07-24","type":"pipeline","source":"CNBC","summary":"Large shareholder group calls for a board overhaul at pharma company CytoDyn - CNBC","headline":"Large shareholder group calls for a board overhaul at pharma company CytoDyn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTE9DZE5CN3pLR2M0UlBVdVY3YVhER0cxQ3A5b2RieFgwWmZwT2E1R2RsZE9zdUJvZkxVbmZNaC1uMEg2UmNBYWlDTlljanIyQkh4RmdteDBfRXU?oc=5","date":"2017-07-21","type":"pipeline","source":"TradingView","summary":"CYDY Stock Price and Chart — OTC:CYDY - TradingView","headline":"CYDY Stock Price and Chart — OTC:CYDY","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}